EX-23.1 7 ex_725367.htm EXHIBIT 23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

| 1. | Registration Statements (Form S-3 Nos. 333-252078, 333-252903, 333-257433, 333-276856 and 333-279941) of Zevra Therapeutics, Inc.,

| 2. | Registration Statement (Form S-8 No. 333-203703) pertaining to the Incentive Stock Plan, as amended, and the 2014 Equity Incentive Plan of Zevra Therapeutics, Inc.,

| 3. | Registration Statements (Form S-8 Nos. 333-210369, 333-216858, 333-224062, 333-230041, 333-236794 and 333-252743) pertaining to the 2014 Equity Incentive Plan of Zevra Therapeutics, Inc.,

| 4. | Registration Statement (Form S-8 No. 333-257429) pertaining to the Amended and Restated 2014 Equity Incentive Plan, and the 2021 Employee Stock Purchase Plan of Zevra Therapeutics, Inc.,

| 5. | Registration Statement (Form S-8 No. 333-270341) pertaining to the 2023 Employment Inducement Award Plan of Zevra Therapeutics, Inc.,

| 6. | Registration Statement (Form S-8 No. 333-278445) pertaining to the Amended and Restated 2023 Employment Inducement Award Plan of Zevra Therapeutics, Inc., and

| 7. | Registration Statements (Form S-8 Nos. 333-270340 and 333-278444) pertaining to the Amended and Restated 2014 Equity Incentive Plan of Zevra Therapeutics, Inc.;

of our report dated March 12, 2025, with respect to the financial statements of Zevra Therapeutics, Inc. included in this Annual Report (Form 10-K) of Zevra Therapeutics, Inc. for the year ended December 31, 2024.

/s/ Ernst & Young LLP

Orlando, Florida

March 12, 2025